<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203098</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-B-J209</org_study_id>
    <nct_id>NCT01203098</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty</brief_title>
  <official_title>A Phase 2b, Randomized, Multi-Dose Efficacy,Safety Study of the Oral Factor Xa Inhibitor DU-176b Versus Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy, safety of DU-176b 30mg or DU-176b
      15mg versus enoxaparin sodium for the prevention of venous thromboembolism in patients after
      elective total hip arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Venous Thromboembolism Events</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.
Lower extremity DVT confirmed by bilateral venography at the end of study treatment
Definite diagnosis of symptomatic PE
Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Bleeding or Clinically Relevant Non-major Bleedings.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Thromboembolism</condition>
  <condition>Thrombosis</condition>
  <condition>Embolism and Thrombosis</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>DU-176b 30mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin sodium twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin sodium 20mg (=2000IU) / 0.2mL twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DU-176b 15mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b 15mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU-176b 15mg</intervention_name>
    <description>DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.</description>
    <arm_group_label>DU-176b 15mg once daily</arm_group_label>
    <other_name>edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU-176b 30mg</intervention_name>
    <description>DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.</description>
    <arm_group_label>DU-176b 30mg once daily</arm_group_label>
    <other_name>edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin sodium 20 mg (=2000IU)</intervention_name>
    <description>Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.</description>
    <arm_group_label>Enoxaparin sodium twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing unilateral total hip arthroplasty

          2. Patients who are 20-84 years olds

        Exclusion Criteria:

          1. Subjects with risks of hemorrhage

          2. Subjects with thromboembolic risks

          3. Subjects who weigh less than 40 kg

          4. Subjects who are pregnant or suspect pregnancy, or subjects who want to become
             pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Fuji</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka Koseinenkin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>January 15, 2015</results_first_submitted>
  <results_first_submitted_qc>February 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2015</results_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>edoxaban</keyword>
  <keyword>anticoagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DU-176b 15 mg</title>
          <description>DU-176b 15 mg tablets, oral once daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>DU-176b 30 mg</title>
          <description>DU-176b 30 mg tablets oral, once daily for 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Enoxaparin Sodium 20mg (2000IU)</title>
          <description>Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Dataset</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of baseline participants reflects the efficacy analysis population</population>
      <group_list>
        <group group_id="B1">
          <title>DU-176b 15 mg</title>
          <description>DU-176b 15 mg tablets, oral once daily for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>DU-176b 30 mg</title>
          <description>DU-176b 30 mg tablets oral, once daily for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Enoxaparin Sodium 20mg (2000IU)</title>
          <description>Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="10.3"/>
                    <measurement group_id="B2" value="60.6" spread="9.6"/>
                    <measurement group_id="B3" value="58.9" spread="10.7"/>
                    <measurement group_id="B4" value="60.3" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Venous Thromboembolism Events</title>
        <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.
Lower extremity DVT confirmed by bilateral venography at the end of study treatment
Definite diagnosis of symptomatic PE
Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE</description>
        <time_frame>2 weeks</time_frame>
        <population>The FAS was defined as all subjects enrolled in the study, but excluded those who had significant GCP violations, who had not received any doses of the study drug, or those who did not develop symptomatic DVT or PE, but in whom venography was not appropriately performed.</population>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 15 mg</title>
            <description>DU-176b 15 mg tablets, oral once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30 mg</title>
            <description>DU-176b 30 mg tablets oral, once daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin Sodium 20mg (2000IU)</title>
            <description>Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Venous Thromboembolism Events</title>
          <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.
Lower extremity DVT confirmed by bilateral venography at the end of study treatment
Definite diagnosis of symptomatic PE
Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE</description>
          <population>The FAS was defined as all subjects enrolled in the study, but excluded those who had significant GCP violations, who had not received any doses of the study drug, or those who did not develop symptomatic DVT or PE, but in whom venography was not appropriately performed.</population>
          <units>percent of participants with VTE event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.0" upper_limit="8.1"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O3" value="4.1" lower_limit="0.0" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Primary analyses were performed on proportion of subjects who experienced thromboembolic events defined as primary efficacy endpoint (incidence of thromboembolic events); incidence of thromboembolic events and its 95% confidence interval (CI) were calculated by treatment group, and difference between DU-176b 15 mg and 30 mg groups and its 95% CI were also calculated. For reference, difference between enoxaparin group and each DU-176b group and its 95% CI of each were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary analyses were performed on proportion of subjects who experienced thromboembolic events defined as primary efficacy endpoint (incidence of thromboembolic events); incidence of thromboembolic events and its 95% confidence interval (CI) were calculated by treatment group, and difference between DU-176b 15 mg and 30 mg groups and its 95% CI were also calculated. For reference, difference between enoxaparin group and each DU-176b group and its 95% CI of each were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Bleeding or Clinically Relevant Non-major Bleedings.</title>
        <time_frame>2 weeks</time_frame>
        <population>The Safety Analysis Set was defined as all subjects who were enrolled in the study, but excluded those who had significant GCP violations, who did not receive any doses of the study drug, or who had no safety data after the start of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 15 mg</title>
            <description>DU-176b 15 mg tablets, oral once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 30 mg</title>
            <description>DU-176b 30 mg tablets oral, once daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin Sodium 20mg (2000IU)</title>
            <description>Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Bleeding or Clinically Relevant Non-major Bleedings.</title>
          <population>The Safety Analysis Set was defined as all subjects who were enrolled in the study, but excluded those who had significant GCP violations, who did not receive any doses of the study drug, or who had no safety data after the start of study treatment</population>
          <units>percentage of subjects with bleeds</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.3" upper_limit="7.9"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.3" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Analysis Set was defined as all subjects who were enrolled in the study, but excluded those who had significant GCP violations, who did not receive any doses of the study drug, or who had no safety data after the start of study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>DU-176b 15 mg</title>
          <description>DU-176b 15 mg tablets, oral once daily for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>DU-176b 30 mg</title>
          <description>DU-176b 30 mg tablets oral, once daily for 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Enoxaparin Sodium 20mg (2000IU)</title>
          <description>Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J V.11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>dislocation of joint prothesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA/J V.11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>stomach discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="89"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E3" events="36" subjects_affected="36" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>gamma glutamyltransferase</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="89"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>blood urine present</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>skin exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Masayuki Fukuzawa, Associate Director</name_or_title>
      <organization>Daiichi Sankyo.,LTD</organization>
      <phone>81-90-5584-2197</phone>
      <email>fukuzawa.masayuki.gn@daiichisankyo.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

